If You Invested in Microbix Biosystems Inc (MBXBF)

Microbix Biosystems Inc. (MBXBF) is a life sciences company that creates proprietary biological products for human health. According to its public disclosures, Microbix focuses on making critical ingredients and devices for the global diagnostics industry, with particular emphasis on antigens for immunoassays and specialized quality assessment materials used by clinical laboratories and diagnostics manufacturers. The company is traded on the Toronto Stock Exchange (TSX) and the OTCQX market, and is headquartered in Mississauga, Ontario, Canada.

Microbix describes itself as a life sciences innovator, manufacturer, and exporter. Its operations center on supplying materials that enable the worldwide commercialization, development, and ongoing quality control of diagnostic assays. The company reports that it employs over 120 skilled staff and generates revenues from the sale of biological products and related materials used in infectious disease testing and clinical laboratory workflows.

Core products and solutions

Microbix states that it makes a wide range of critical ingredients and devices for diagnostics. A key focus is the production of antigens for immunoassays, which are used by diagnostics makers to create antibody-based tests. The company reports that its antigens drive the antibody tests of approximately 100 diagnostics manufacturers around the world.

Another major area is its laboratory quality assessment products (QAPs™) and reference materials (QUANTDx™). These products are described as supporting clinical laboratory proficiency testing and external quality assessment programs, enabling assay development and validation, and helping ensure the quality of clinical diagnostic workflows. Microbix indicates that QAPs and QUANTDx are supplied to clinical lab accreditation organizations, diagnostics companies, and clinical laboratories, and that its QAPs are available in more than 30 countries through a network of international distributors.

Expertise in native and recombinant antigens

Microbix reports over 40 years of expertise in the technically challenging manufacturing of native viral antigens. This work involves culturing mammalian host cells, introducing target viruses into those cells, and then extracting, purifying, and inactivating high-quality viral components suitable for infectious-disease tests at commercial scale.

Building on this background, the company has also extended its capabilities into recombinant (synthetic) antigen production. It has announced the development and commercialization of a recombinant nucleocapsid protein of the SARS-CoV-2 virus (COVID-19). This recombinant antigen is used within Microbix QAPs to support clinical laboratory proficiency testing and external quality assessment programs, and is also made available at commercial scale for test manufacturers. Microbix notes that in-house recombinant production can improve supply-chain security and provide better control of manufacturing costs.

Applications in diagnostics and laboratory quality

According to Microbix, its QAPs and reference materials are used in several key applications:

• Supporting clinical lab proficiency testing and external quality assessment programs.
• Enabling assay development and validation for diagnostics companies.
• Helping ensure the ongoing quality of clinical diagnostic workflows in laboratories and other testing sites.

The company indicates that its SARS-CoV-2 antigen QAPs address quality assessment needs for antigen-based testing of this virus and represent a meaningful portion of overall QAPs sales. Microbix positions its antigen and QAPs offerings as tools that help measure and characterize disease responses in human populations, which is important for both diagnostic test design and external quality assessment.

Other proprietary products and technologies

Beyond its antigen and QAPs businesses, Microbix reports that it applies its biological expertise and infrastructure to other proprietary products and technologies. Notably, it highlights:

• Kinlytic® urokinase, described as a biologic thrombolytic drug used to treat blood clots.
• Reagents and media to support diagnostic testing, including its DxTM™ product for patient-sample collection.

These additional products reflect the company’s broader use of its biologics and manufacturing capabilities in areas related to diagnostics and therapeutic applications.

Regulatory and quality accreditations

Microbix emphasizes a range of regulatory and quality credentials that support its role in the diagnostics supply chain. The company states that it is:

• ISO 9001 and ISO 13485 accredited, indicating quality management systems for general and medical device-related processes.
• U.S. FDA registered.
• Australian TGA registered.
• Health Canada establishment licensed.
• A provider of IVDR-compliant CE marked products for applicable markets.

These accreditations and registrations are presented by Microbix as supporting its ability to supply products to regulated diagnostics and clinical laboratory markets in multiple jurisdictions.

Global reach and customer base

Microbix reports that its QAPs are available in over 30 countries and are supported by international distributors. Its antigens are used by approximately 100 diagnostics makers. The company indicates that its QAPs and QUANTDx products are sold to clinical lab accreditation organizations, diagnostics companies, and clinical laboratories, reflecting a customer base that spans multiple parts of the diagnostics ecosystem.

Corporate governance and disclosure practices

In its public communications, Microbix has described interactions with securities regulators regarding disclosure practices. For example, it has noted that staff of the Ontario Securities Commission (OSC) reviewed its continuous disclosure materials and provided comments on the company’s use of non-IFRS financial measures such as EBITDA in investor presentations. Microbix has stated that it updated its investor presentation and other disclosure materials to align with applicable rules and guidance, including the requirements of National Instrument 52-112 for non-GAAP and other financial measures.

The company’s news releases also contain cautionary language about forward-looking information, highlighting that statements about future events, conditions, or results are inherently uncertain and may differ from actual outcomes. Microbix notes that it is under no obligation to update such forward-looking information except as required by law.

Stock information

Microbix Biosystems Inc. is listed on the Toronto Stock Exchange (TSX) under the symbol MBX and trades on the OTCQX market under the symbol MBXBF. These listings provide access to both Canadian and U.S. investors interested in the company’s life sciences and diagnostics-related activities.